Beta Drugs Limited

Beta Drugs - Annual Report excerpt

• We delivered our highest annual growth ever. The company’s FY22 revenues grew by 58% to Rs 183.84crores while consolidated EBITDA grew by 72% to Rs 43.5 crores from 25.24 crores compared with the year-ago period. EBITDA margins expanded to 23.6% from 21.7. Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.

• The company is poised for strong growth for the next few years on the back of its strong R&D efforts to develop complex generics in the oncology space and continued expansion into new geographies. Beta is focused on getting plant approvals and has many inspections/ audits lined up for this year. It is continuing to file new product registrations across the ROW countries and is poised to enter regulated markets soon.

• Beta Drugs’ strong product pipeline of twenty-three products which are going off-patent in next five years includes NIBs, NDDS & PARP inhibitors which will continue to support top line and margin expansion.

• The company is also expanding its API capabilities by developing new products. It plans to file CEP by Oct 2022. This backward integration helps the company to continuously expand its margins. The company has further got an allotment of 12 acres of land on 95years lease in a special area allocated for API & intermediates, where there is a single-window. This will help the company to take care of its future API capacity expansion

• Beta has also entered into long term partnerships with three multinational pharma companies for its CMO business.

• We believe that all our segments are slated to clock healthy growth with EBITDA margins in the range of 24% to 25%.

• The company is in the midst of developing new drug delivery systems, new dosage formulations and applying the latest technology for better processes.